Drug Profile

SPC 15

Alternative Names: SPC-15

Latest Information Update: 23 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Columbia University
Developer Silo Pharma
Class Antidepressants; Anxiolytics
Mechanism of Action Serotonin 4 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Anxiety disorders; Post-traumatic stress disorders

Most Recent Events

18 Feb 2026 Silo Pharma receives Notice of Allowance for SPC 15 in Japan
23 Oct 2025 Silo expected to conduct meeting with US FDA to confirm the final data points needed to open an IND before year-end in Post-traumatic stress disorders in November 2025
23 Oct 2025 Silo Pharma plans to submit IND to US FDA for Post-traumatic stress disorder and Anxiety disorders in 2026 (Intranasal).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com